Zhang, Huiyuan
Du, Yuchen
Qi, Lin
Xiao, Sophie
Braun, Frank K.
Kogiso, Mari
Huang, Yulun
Huang, Frank
Abdallah, Aalaa
Suarez, Milagros
Karthick, Sekar
Ahmed, Nabil M.
Salsman, Vita S.
Baxter, Patricia A.
Su, Jack M.
Brat, Daniel J.
Hellenbeck, Paul L.
Teo, Wan-Yee
Patel, Akash J.
Li, Xiao-Nan http://orcid.org/0000-0002-6719-3789
Funding for this research was provided by:
NIH/NCI (RO1 CA185402)
Article History
Received: 7 March 2023
Accepted: 30 May 2023
First Online: 6 July 2023
Declarations
:
: Patient tumor samples were collected following an Institutional Review Board (IRB) of Baylor College of Medicine approved human protocol after obtaining written consent from the patients. All the animal experiments were performed following Institutional Animal Care and Use Committee (IACUC) approved animal protocols from Baylor College of Medicine and Northwestern University.
: All authors read and approved the final manuscript.
: Paul L. Hellenbeck is an employee of Seneca Therapeutics, all other authors declare no potential conflicts of interest.